Carcinogens that induce the A:T>T:A nucleotide substitutions in the genome

doi:10.1007/s11684-017-0611-y

Front. Med.

2018, Vol. 12

Issue (2) : 236-238 https://doi.org/10.1007/s11684-017-0611-y

COMMENTARY

Carcinogens that induce the A:T>T:A nucleotide substitutions in the genome

Guangbiao Zhou(

), Xinchun Zhao

State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China

Download: PDF(81 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Recently, Ng et al. reported that the A:T>T:A substitutions, proposed to be a signature of aristolochic acid (AA) exposure, were detected in 76/98 (78%) of patients with hepatocellular carcinoma (HCC) from the Taiwan Province of China, and 47% to 1.7% of HCCs from the Chinese mainland and other countries harbored the nucleotide changes. However, other carcinogens, e.g., tobacco carcinogens 4-aminobiphenyl and 1,3-butadiene, air toxic vinyl chloride and its reactive metabolites chloroethylene oxide, melphalan and chlorambucil, also cause this signature in the genome. Since tobacco smoke is a worldwide public health threat and vinyl chloride distributes globally and is an air pollutant in Taiwan Province, the estimation of the patients’ exposure history is the key to determine the “culprit” of the A:T>T:A mutations. Apparently, without estimation of the patients’ exposure history, the conclusion of Ng et al. is unpersuasive and misleading.

Keywords genomic signature carcinogen aristolochic acid tobacco smoke vinyl chloride hepatocellular carcinoma

Corresponding Author(s): Guangbiao Zhou

Just Accepted Date: 08 November 2017 Online First Date: 01 December 2017 Issue Date: 02 April 2018

Cite this article:

Guangbiao Zhou,Xinchun Zhao. Carcinogens that induce the A:T>T:A nucleotide substitutions in the genome[J]. Front. Med., 2018, 12(2): 236-238.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-017-0611-y
https://academic.hep.com.cn/fmd/EN/Y2018/V12/I2/236

Tab.1 Carcinogens causing the A:T>T:A nucleotide substitutions

1	Ng AWT, Poon SL, Huang MN, Lim JQ, Boot A, Yu W, Suzuki Y, Thangaraju S, Ng CCY, Tan P, Pang ST, Huang HY, Yu MC, Lee PH, Hsieh SY, Chang AY, Teh BT, Rozen SG. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci Transl Med 2017; 9(412): eaan6446 https://doi.org/10.1126/scitranslmed.aan6446 pmid: 29046434
2	De Broe ME. On a nephrotoxic and carcinogenic slimming regimen. Am J Kidney Dis 1999; 33(6): 1171–1173 https://doi.org/10.1016/S0272-6386(99)70159-9 pmid: 10352210
3	Stiborová M, Arlt VM, Schmeiser HH. Balkan endemic nephropathy: an update on its aetiology. Arch Toxicol 2016; 90(11): 2595–2615 https://doi.org/10.1007/s00204-016-1819-3 pmid: 27538407
4	de Jonge H, Vanrenterghem Y. Aristolochic acid: the common culprit of Chinese herbs nephropathy and Balkan endemic nephropathy. Nephrol Dial Transplant 2008; 23(1): 39–41 https://doi.org/10.1093/ndt/gfm667 pmid: 17913731
5	Schmeiser HH, Janssen JWG, Lyons J, Scherf HR, Pfau W, Buchmann A, Bartram CR, Wiessler M. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res 1990; 50(17): 5464–5469 pmid: 2201437
6	Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelić M, Jelaković B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 2007; 104(29): 12129–12134 https://doi.org/10.1073/pnas.0701248104 pmid: 17620607
7	Yu XJ, Yang MJ, Zhou B, Wang GZ, Huang YC, Wu LC, Cheng X, Wen ZS, Huang JY, Zhang YD, Gao XH, Li GF, He SW, Gu ZH, Ma L, Pan CM, Wang P, Chen HB, Hong ZP, Wang XL, Mao WJ, Jin XL, Kang H, Chen ST, Zhu YQ, Gu WY, Liu Z, Dong H, Tian LW, Chen SJ, Cao Y, Wang SY, Zhou GB. Characterization of somatic mutations in air pollution-related lung cancer. EBioMedicine 2015; 2(6): 583–590 https://doi.org/10.1016/j.ebiom.2015.04.003 pmid: 26288819
8	Chappell G, Pogribny IP, Guyton KZ, Rusyn I. Epigenetic alterations induced by genotoxic occupational and environmental human chemical carcinogens: a systematic literature review. Mutat Res Rev Mutat Res 2016; 768(Supplement C): 27–45 https://doi.org/10.1016/j.mrrev.2016.03.004 pmid: 27234561
9	Manjanatha MG, Li EE, Fu PP, Heflich RH. H- and K-ras mutational profiles in chemically induced liver tumors from B6C3F1 and CD-1 mice. J Toxicol Environ Health 1996; 47(2): 195–208 https://doi.org/10.1080/009841096161898 pmid: 8598575
10	Ma H, Wood TG, Ammenheuser MM, Rosenblatt JI, Ward JB Jr. Molecular analysis of hprt mutant lymphocytes from 1, 3-butadiene-exposed workers. Environ Mol Mutagen 2000; 36(1): 59–71 https://doi.org/10.1002/1098-2280(2000)36:1<59::AID-EM9>3.0.CO;2-# pmid: 10918361
11	Wagoner JK. Toxicity of vinyl chloride and poly(vinyl chloride): a critical review. Environ Health Perspect 1983; 52:61–66 pmid: 6360677
12	Hollstein M, Marion MJ, Lehman T, Welsh J, Harris CC, Martel-Planche G, Kusters I, Montesano R. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 1994; 15(1): 1–3 https://doi.org/10.1093/carcin/15.1.1 pmid: 8293534
13	Wang P, Bennett RAO, Povirk LF. Melphalan-induced mutagenesis in an SV40-based shuttle vector: predominance of A·T→T·A transversions. Cancer Res 1990; 50(23): 7527–7531 pmid: 2174727
14	Povirk LF, Shuker DE. DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res 1994; 318(3): 205–226 https://doi.org/10.1016/0165-1110(94)90015-9 pmid: 7527485
15	Hoang ML, Chen CH, Sidorenko VS, He J, Dickman KG, Yun BH, Moriya M, Niknafs N, Douville C, Karchin R, Turesky RJ, Pu YS, Vogelstein B, Papadopoulos N, Grollman AP, Kinzler KW, Rosenquist TA. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med 2013;5(197):197ra02 https://doi.org/DOI: 10.1126/scitranslmed.3006200 pmid: 23926200
16	Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, Chong SC, Gan A, Tay ST, Lim WK, Cutcutache I, Huang D, Ler LD, Nairismägi ML, Lee MH, Chang YH,Yu KJ, Chan-On W, Li BK, Yuan YF, Qian CN, Ng KF, Wu CF, Hsu CL, Bunte RM, Stratton MR, Futreal PA, Sung WK, Chuang CK, Ong CK, Rozen SG,Tan P, Teh BT. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med 2013; 5(197):197ra101 https://doi.org/10.1126/scitranslmed.3006086 pmid: 23926199
17	Houle CD, Ton TVT, Clayton N, Huff J, Hong HHL, Sills RC. Frequent p53 and H-ras mutations in benzene- and ethylene oxide-induced mammary gland carcinomas from B6C3F1 mice. Toxicol Pathol 2006; 34(6): 752–762 https://doi.org/10.1080/01926230600935912 pmid: 17162533
18	Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, Zhu ZD, Zhou B, Liu XY, Liu RF, Fei QL, Chen H, Cai B, Zhou B, Xiao HS, Qin LX, Han ZG. Exome sequencing of hepatitis B virus-associated hepatoccelular carcinoma. Nat Genet 2012; 44(10): 1117–1121
19	Tsai WT. Current status of air toxics management and its strategies for controlling emissions in Taiwan. Toxics 2016; 4(2):8 https://doi.org/10.3390/toxics4020008 pmid: 29051413

[1]	Yanfei Zhang, Xinchun Zhao, Yongchun Zhou, Min Wang, Guangbiao Zhou. *Identification of an E3 ligase-encoding gene RFWD3* in non-small cell lung cancer**[J]. Front. Med., 2020, 14(3): 318-326.
[2]	Amy Lee, Fa-Chyi Lee. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check[J]. Front. Med., 2020, 14(3): 273-283.
[3]	Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen. Adoptive cell transfer therapy for hepatocellular carcinoma[J]. Front. Med., 2019, 13(1): 3-11.
[4]	Shasha Zhu, Huimin Zhang, Li Bai. NKT cells in liver diseases[J]. Front. Med., 2018, 12(3): 249-261.
[5]	Min Yu, Zonghai Li. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches[J]. Front. Med., 2017, 11(4): 509-521.
[6]	Zhen He,Cheng Hu,Weiping Jia. miRNAs in non-alcoholic fatty liver disease[J]. Front. Med., 2016, 10(4): 389-396.
[7]	Xinsen Xu,Yanyan Zhou,Runchen Miao,Wei Chen,Kai Qu,Qing Pang,Chang Liu. Transcriptional modules related to hepatocellular carcinoma survival: coexpression network analysis[J]. Front. Med., 2016, 10(2): 183-190.
[8]	Zhi Xu,Chunxiang Cao,Haiyan Xia,Shujing Shi,Lingzhi Hong,Xiaowei Wei,Dongying Gu,Jianmin Bian,Zijun Liu,Wenbin Huang,Yixin Zhang,Song He,Nikki Pui-Yue Lee,Jinfei Chen. Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma[J]. Front. Med., 2016, 10(1): 52-60.
[9]	Felice Ho-Ching Tsang,Sandy Leung-Kuen Au,Lai Wei,Dorothy Ngo-Yin Fan,Joyce Man-Fong Lee,Carmen Chak-Lui Wong,Irene Oi-Lin Ng,Chun-Ming Wong. MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility[J]. Front. Med., 2015, 9(3): 331-343.
[10]	Farhad Sahebjam,John M. Vierling. Autoimmune hepatitis[J]. Front. Med., 2015, 9(2): 187-219.
[11]	Guanghua Rong,Wenlin Bai,Zheng Dong,Chunping Wang,Yinying Lu,Zhen Zeng,Jianhui Qu,Min Lou,Hong Wang,Xudong Gao,Xiujuan Chang,Linjing An,Yan Chen,Yongping Yang. Cryotherapy for cirrhosis-based hepatocellular carcinoma: a single center experience from 1595 treated cases[J]. Front. Med., 2015, 9(1): 63-71.
[12]	Kai Qu,Ting Lin,Zhixin Wang,Sinan Liu,Hulin Chang,Xinsen Xu,Fandi Meng,Lei Zhou,Jichao Wei,Minghui Tai,Yafeng Dong,Chang Liu. Reactive oxygen species generation is essential for cisplatin-induced accelerated senescence in hepatocellular carcinoma[J]. Front. Med., 2014, 8(2): 227-235.
[13]	Du Yan, Han Xue, Pu Rui, Xie Jiaxin, Zhang Yuwei, Cao Guangwen. Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk[J]. Front. Med., 2014, 8(2): 217-226.
[14]	Marielle Reataza,David K. Imagawa. Advances in managing hepatocellular carcinoma[J]. Front. Med., 2014, 8(2): 175-189.
[15]	Lunxiu Qin. Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies[J]. Front Med, 2014, 8(1): 24-32.

Viewed

Full text

Abstract

Cited

Shared

Discussed